Core Viewpoint - On June 20, a total of 9 stocks on the Sci-Tech Innovation Board experienced block trading, with a cumulative transaction amount of 77.84 million yuan [1][2]. Group 1: Trading Overview - There were 14 block trades executed, totaling 3.64 million shares and an aggregate transaction value of 77.84 million yuan [1]. - The stock with the highest transaction amount was Hongsoft Technology, with 2 block trades totaling 448,000 shares and a transaction value of 17.92 million yuan [1]. - Other notable stocks in terms of transaction value included Zhuhai Guanyu and Delong Laser, with transaction amounts of 15.83 million yuan and 9.48 million yuan, respectively [1]. Group 2: Price and Performance Analysis - The average discount rates for block trades relative to the closing prices were highest for Zhongyou Technology, Hongsoft Technology, and Chengdu Xian Dao, with discount rates of 13.40%, 10.25%, and 9.49% respectively [1]. - The only stock with a premium was Transsion Holdings, which had a premium rate of 1.96% [1]. - The Sci-Tech 50 Index fell by 0.53%, with 170 stocks rising, accounting for 28.91% of the total [1]. - Among the stocks involved in block trading, the average decline was 2.04%, with Delong Laser and Jinghe Integration showing gains of 2.86% and 0.41%, while Zhongyou Technology, Jingye Intelligent, and Ankai Micro experienced declines of 7.58%, 3.87%, and 3.51% respectively [1]. Group 3: Institutional Participation - Among the block trades, there were 5 transactions involving institutional buyers or sellers across 4 stocks [2]. - The leading stocks for institutional buying were Hongsoft Technology and Delong Laser, with amounts of 10.92 million yuan and 9.48 million yuan respectively [2]. - The stocks with the highest institutional selling amounts were Zhongyou Technology and Jingye Intelligent, with amounts of 8.40 million yuan and 2.00 million yuan respectively [2]. Group 4: Capital Flow - Two stocks saw net inflows of capital, with Hongsoft Technology and Jinghe Integration receiving net inflows of 234,790 yuan and 1,310 yuan respectively [2]. - Conversely, the stocks with the highest net outflows included Zhongyou Technology, Chengdu Xian Dao, and Ankai Micro, with net outflows of 49.71 million yuan, 11.33 million yuan, and 10.03 million yuan respectively [2].

Summary of Key Points Core Viewpoint - The announcement details the share reduction by the major shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Device Co., Ltd., which has reduced its stake in Chengdu Xian Dao Pharmaceutical Development Co., Ltd. by 2,000,000 shares, representing 0.50% of the total share capital. Group 1: Shareholder Background - Before the reduction plan, Huabo Medical held 46,770,579 shares, accounting for 11.67% of the total share capital, with these shares acquired prior to the company's IPO and released for trading on April 16, 2021 [1][2]. - Huabo Medical is identified as a direct shareholder holding more than 5% of the shares [2]. Group 2: Reduction Plan Implementation - The reduction plan was disclosed on March 3, 2025, with the intention to sell shares through centralized bidding from March 24, 2025, to June 23, 2025, with a limit of 1% of the total shares within any 90-day period [1]. - The actual reduction occurred between April 18, 2025, and June 19, 2025, with a total of 2,000,000 shares sold [2][4]. Group 3: Financial Details of the Reduction - The shares were sold at a price range of 14.66 to 17.79 yuan per share, resulting in a total reduction amount of 31,753,578.19 yuan [3]. - After the reduction, Huabo Medical holds 44,770,579 shares, which is 11.17% of the total share capital [3][4].

Summary of Chengdu XianDao Conference Call Company Overview - Chengdu XianDao focuses on drug discovery and development, leveraging DEL technology and AI to enhance efficiency in molecular optimization and project success rates [2][15][16]. Key Technologies and Platforms - **Halo Platform**: Integrates DEL technology with AI for high-throughput experiments and rapid molecular optimization, utilizing SAR data [2][15]. - **DMTA High-Throughput Molecular Optimization Platform**: Under development, includes Design, Make, Test, and Analyze phases for continuous molecular optimization [5][6]. - **AI in Drug Discovery**: The company has accumulated over 6,000 protein complex structures, 1.2 trillion compound structures, and nearly 1,000 target experimental data, forming a unique "lead model" for rapid compound testing [2][15]. Clinical Development - **HG146 Pipeline**: Targeting HDAC for solid tumors, currently in Phase II clinical trials with over 20 head and neck cancer patients enrolled. More data expected in Q4 2025 [2][10][26]. - **Second-Generation Small Molecule Inhibitor Project (3,918)**: Focused on AAA and AF diseases, with three preclinical candidates identified. The company seeks partnerships for further development [2][11]. Financial Performance - The biopharmaceutical sector performed well in Q1 2025, with stable year-on-year growth in R&D investment and commercial conversion rates [3][12][14]. - The company is undergoing a merger with a firm specializing in specialty formulations, which is expected to enhance innovation and market reach [4][14]. Collaborations and Market Position - Successful collaboration with Xiantong Bio in nucleic acid drug production, completing the first commercial project. However, the CDMO nucleic acid market is competitive with lower profit margins [4][30]. - The company is exploring international collaborations and has participated in events like the Boston Bio Conference to enhance its global presence [27]. Challenges and Risks - The company acknowledges the risks associated with early-stage projects and the competitive landscape in the CDMO market, particularly in nucleic acid drugs [4][30]. - AI technology has not yet reached widespread industrial application, with varying project outcomes [21]. Future Outlook - Chengdu XianDao aims to continue expanding its capabilities in AI-driven drug discovery and molecular optimization, with a focus on enhancing its commercial offerings and maintaining healthy growth rates [12][15][20].

证券代码：688222 证券简称：成都先导 公告编号：2025-025 成都先导药物开发股份有限公司 股东拉萨经济技术开发区华博医疗器械有限公司 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持计划实施前股东持股的基本情况 | 股东名称 | 拉萨经济技术开发区华博医疗器械有限公司 | | | | | --- | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | | □是 | √否 | | | 直接持股 | 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | | □是 | √否 | | | 其他： | | | | | 持股数量 | 46,770,579股 | | | | | 持股比例 | 11.67% | | | | | 当前持股股份来源 | IPO 前取得：46,770,579股 | | | | 上述减持主体无一致行动人。 二、减持计划的实施结果 （一）大股东因以下事项披露减持计划实施结果： 减持 ...

成都先导公告，股东拉萨经济技术开发区华博医疗器械有限公司在2025年4月18日至2025年6月19日期 间，通过集中竞价交易方式累计减持公司股份200万股，占公司总股本的0.50%。减持价格区间为14.66 元/股至17.79元/股，减持总金额为3175.36万元。减持后，华博器械持有公司股份4477.06万股，占公司 总股本的11.17%。此次减持计划与此前披露的一致，且已实施完毕。 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-024 成都先导药物开发股份有限公司 为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 被担保人：Vernalis (R&D) Limited（以下简称"Vernalis"），系成都先导药 物开发股份有限公司（以下简称"成都先导"或"公司"）的全资子公司。 ? Vernalis 拟继续承租位于英国剑桥郡大阿宾顿格兰塔公园 GP3 的房产 （以 下简称"租赁物业"）作为办公场所用于研发和运营，与 BMR GRANTA PARK PROPCO LIMITED（一家注册于英国马恩岛的公司，以下简称"BMR"）拟签署 《复归租约》。租赁期限自 2026 年 9 月 29 日至 2028 年 3 月 28 日。基本租金为： 自 2027 年 9 月 29 日起，每年 1,023,347.55 英镑（不含增值税）。本次租赁项下， 公司将为 Vernalis 按照《复归租约》的约定支付所有款项及义务提供担保（以下 简称"本次担保 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-024 成都先导药物开发股份有限公司 为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 被担保人：Vernalis (R&D) Limited（以下简称"Vernalis"），系成都先导药 物开发股份有限公司（以下简称"成都先导"或"公司"）的全资子公司。 Vernalis 拟继续承租位于英国剑桥郡大阿宾顿格兰塔公园 GP3 的房产（以 下简称"租赁物业"）作为办公场所用于研发和运营，与 BMR GRANTA PARK PROPCO LIMITED（一家注册于英国马恩岛的公司，以下简称"BMR"）拟签署 《复归租约》。租赁期限自 2026 年 9 月 29 日至 2028 年 3 月 28 日。基本租金为： 2026 年 9 月 29 日至 2027 年 9 月 28 日，每年 993,541.30 英镑（不含增值税）； 自 2027 年 9 月 29 日起，每年 1,023,347.55 英镑（不含增值税）。本次租赁 ...

Core Viewpoint - The company has announced a cash dividend of 0.06 yuan per share, approved at the 2024 annual general meeting held on May 23, 2025 [1][2]. Dividend Distribution Plan - The dividend distribution is based on the total share capital minus shares held in the company's repurchase account, with a total of 399,441,300 shares eligible for distribution [2][4]. - The total cash dividend to be distributed amounts to 23,966,478.00 yuan (including tax) [2]. - The company will not issue bonus shares or capital reserves, and the distribution will only involve cash dividends [2][4]. Implementation Method - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited Shanghai Branch to shareholders registered by the end of the trading day on the record date [5]. - Shareholders who have completed designated transactions can receive their cash dividends on the payment date, while those who have not will have their dividends held until they complete the necessary transactions [5]. Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.06 yuan per share [8]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and deducted upon the sale of shares [8]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% corporate income tax withheld, resulting in a net distribution of 0.054 yuan per share [9].

Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

成都高新区交子大道 233 号 中海国际中心 C 座 28 层 邮编：610041 电话：(86-28) 6739-8000 传真：(86-28) 6739-8001 junhecd@junhe.com 北京君合（成都）律师事务所 关于成都先导药物开发股份有限公司 差异化分红事项的法律意见书 致：成都先导药物开发股份有限公司 北京君合（成都）律师事务所（以下简称"本所"）受成都先导药物开发股 份有限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下 简称《公司法》）、《中华人民共和国证券法》《上市公司股份回购规则》（以下简 称《回购规则》）、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》 （以下简称《回购股份指引》）等相关法律、法规及规范性文件以及《成都先导 药物开发股份有限公司章程》（以下简称《公司章程》）的有关规定，就公司 2024 年度利润分配涉及的差异化分红相关事项（以下简称"本次差异化分红"）出具 本法律意见书。 为出具本法律意见书，本所审查了公司提供的有关文件及其复印件，并取得 公司向本所作出的如下保证：公司已向本所提供了出具本法律意见书所必须的、 真实、完整的原始书 ...